Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off
Close

Quince Therapeutics Inc (QNCX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Quince Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.36 +0.04    +3.41%
13:46:06 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 70,708
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 1.31 - 1.40
Quince Therapeutics 1.36 +0.04 +3.41%

Quince Therapeutics Inc Company Profile

 
Get an in-depth profile of Quince Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

21

Equity Type

ORD

Quince Therapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on advancing precision therapeutics for debilitating and rare diseases. The Company is focused on novel therapeutic approaches to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. The Company’s lead compound, NOV004, is a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. NOV004 is designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing. The Company's discovery pipeline is potentially applicable across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases.

Contact Information

Address 601 Gateway Blvd Ste 1250
South San Francisco, 94080
United States
Phone 415 910 5717
Fax -

Top Executives

Name Age Since Title
Marwan Sabbagh - - Member of Clinical Advisory Board
Christopher J. Senner 54 2019 Independent Director
David A. Lamond 47 2015 Independent Chairman of the board
Dirk Thye 53 2022 CEO & Director
Una S. Ryan 82 2019 Lead Independent Director
Martin Rhys Farlow - - Member of Clinical Advisory Board
Ted Yednock 66 - Member of Scientific Advisory Board
Eric M. Gordon - - Member of Scientific Advisory Board
Jan Potempa - - Member of Scientific Advisory Board
Mark Brody - - Member of Clinical Advisory Board
Richard C. White - - Member of Scientific Advisory Board
Mathew Bogyo - - Member of Scientific Advisory Board
Lon S. Schneider - 2019 Member of Clinical Advisory Board
Jeffrey L. Cummings 75 2019 Member of Clinical Advisory Board
Thomas P. Laughren - 2019 Clinical Advisory Board Member
Pierre N. Tariot - 2019 Member of Clinical Advisory Board
David A. Lowe 77 - Member of Scientific Advisory Board
Margaret A. McLoughlin 61 2015 Independent Director
Ilan Zipkin - - Member of Scientific Advisory Board
Clive Holmes - 2020 Clinical Advisory Board Member
Mark Ryder - - Member of Clinical Advisory Board
David Munoz - - Member of Clinical Advisory Board
Merce Boada - 2020 Member of Clinical Advisory Board
Susan Perlman - 2024 Member of Scientific Advisory Board
Mauro Magnani - 2024 Chairman of Scientific Advisory Board
James A. Spudich 82 2024 Member of Scientific Advisory Board
Luca Benatti 63 2023 Director
Vladimir R. Muzykantov - 2024 Member of Scientific Advisory Board
Carlo Brugnara - 2024 Member of Scientific Advisory Board
June Bray 69 2022 Independent Director
William Jusko - 2024 Member of Scientific Advisory Board
Rajiv Patni 55 2024 Director
Howard Lederman - 2024 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

QNCX Comments

Write your thoughts about Quince Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Crim Jamer
Crim Jamer Feb 09, 2023 1:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$1 is a good price unless you bought it for higher
Crim Jamer
Crim Jamer Jan 27, 2023 12:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Now i only need +1500% to breakeven
Crim Jamer
Crim Jamer Nov 04, 2022 6:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Can't hold $1, total loss
MIKHAIL KUZNETSOV
MIKHAIL KUZNETSOV Jan 30, 2022 7:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Well, we'll have to buy this failure for $5.9 soon we'll see fireworks here and witness how she will go crazy. I expect double digits.
Crim Jamer
Crim Jamer Jan 30, 2022 7:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
You can buy it now under 3
Crim Jamer
Crim Jamer Jan 30, 2022 7:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
under 2?
Crim Jamer
Crim Jamer Jan 30, 2022 7:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1 maybe?
Crim Jamer
Crim Jamer Jan 27, 2022 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Going to zero
Crim Jamer
Crim Jamer Dec 27, 2021 1:47PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
15% intraday price action. Shorters are in charge because of T/L selling EOY. They must cover.
Mike Ca
Mike Ca Dec 09, 2021 7:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I love a good potential Squeeze setup especially when its "Numero uno," on the largest Shorts Vs the Float list.
Chuong Doan
Chuong Doan Dec 01, 2021 1:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
something is going on. it will go up to 30 soon
Crim Jamer
Crim Jamer Dec 01, 2021 1:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is the price target from HC Hainwright (they corrected it from 200, LOL).
Crim Jamer
Crim Jamer Nov 22, 2021 1:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
We may get Alzheimer earlier than break-even.
Crim Jamer
Crim Jamer Nov 04, 2021 2:58PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This algo trading confuses all technical analysis.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email